New and Emerging Options for the Management of MS: A Conversation With Dr. Lublin скачать в хорошем качестве

New and Emerging Options for the Management of MS: A Conversation With Dr. Lublin

This video is available for 0.5 AMA PRA Category 1 Credit(s)™ Click here to view CME and claim credit: https://www.francefoundation.com/aims... Listen in as June Halper (CEO, The Consortium of Multiple Sclerosis Centers) and Dr. Fred Lublin (Saunders Family Professor of Neurology, Icahn School of Medicine) discuss the newer and emerging options for MS management, as well as what the future of MS treatment looks like. For more education from this series click here: https://www.cmeaims.org/?utm_source=Y... Fred D. Lublin, MD, has served as a speaker for Sanofi. He has done research for Actelion, Biogen, Brainstorm Cell Therapeutics, The National Institute of Health, The National Multiple Sclerosis Society, Novartis Pharmaceuticals, and Sanofi. He has also consulted and served on advisory boards for Acorda, Actelion/Janssen, Apitope, Atara, Avotres, Biotherapeutics, Biogen Idec, Brainstorm Cell Therapeutics, EMD Serono, GW Pharma, Immunic, Innate Immunotherapeutics, Jazz Pharmaceuticals, Mapi Pharma, Medday, MedImmune/Viela Bio, Mylan, Novartis, Orion Biotechnology, Polpharma, Population Council, Receptos/Celgene, Genentech/Roche, Sanofi/Genzyme, Teva, and TG Therapeutics. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. This information is intended for health care providers. This activity is supported by an educational grant from Biogen and Sanofi Genzyme.